Nucleolin and ErbB2 inhibition reduces tumorigenicity of ErbB2-positive breast cancerEya Wolfson(Tel Aviv University), Ronit Pinkas‐Kramarski(Tel Aviv University)Cell Death and DiseaseJanuary 19, 201810.1038/s41419-017-0067-7Cited by 43SaveCiteExport RISWatch citationsRelated PapersNucleolin-binding by ErbB2 enhances tumorigenicity of ErbB2-positive breast cancer|Oncotarget|2016|38Nucleolin inhibitor GroA triggers reduction in epidermal growth factor receptor activation: Pharmacological implication for glial scarring after spinal cord injury|Journal of Neurochemistry|2016|10Continuous treatment with FTS confers resistance to apoptosis and affects autophagy|PLoS ONE|2017|4